Celldex Therapeutics, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Celldex Therapeutics, Inc. (CLDX) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$10.24 million for the 3-month period ending 2011-06-30, per its 10-Q filed 2011-08-04.
Discontinued › Income Statement
us-gaap:ProfitLoss · last filed 2011-08-04
- Celldex Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2011-06-30 was -$10.24M.
- Celldex Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2010-06-30 was -$9.53M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month |
|---|---|---|
| 2011-06-30 | -$10.24M 10-Q · filed 2011-08-04 | -$20.30M 10-Q · filed 2011-08-04 |
| 2010-06-30 | -$9.53M 10-Q · filed 2011-08-04 | -$16.11M 10-Q · filed 2011-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |